Long-term survivors and gilteritinib safety beyond 1 year in patients with FLT3-mutated relapsed or refractory acute myeloid leukemia: ADMIRAL trial follow-up

被引：0

作者：

Perl, Alexander E. ^{[1
]}

Martinelli, Giovanni ^{[2
]}

Neubauer, Andreas ^{[3
]}

Berman, Ellin ^{[4
]}

Baer, Maria R. ^{[5
]}

Larson, Richard A. ^{[6
]}

Fathi, Amir T. ^{[7
]}

Yokoyama, Hisayuki ^{[8
]}

Hosono, Naoko ^{[9
]}

Hasabou, Nahla ^{[10
]}

Lu, Qiaoyang ^{[10
]}

Tiu, Ramon V. ^{[10
]}

机构：

[1] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[2] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Meldola, Italy

[3] Univ Klinikum Giessen & Marburg GmbH, Marburg, Germany

[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[5] Univ Maryland, Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA

[6] Univ Chicago, Chicago, IL 60637 USA

[7] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA

[8] Natl Hosp Org, Sendai Med Ctr, Sendai, Miyagi, Japan

[9] Univ Fukui, Fukui, Japan

[10] Astellas Pharma US Inc, Northbrook, IL USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2021年 / 193卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BSH2021-OR

引用

页码：3 / 4

页数：2

共 50 条

[21] Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial
Perl, Alexander E.
Martinelli, Giovanni
Cortes, Jorge E.
Neubauer, Andreas
Berman, Ellin
Paolini, Stefania
Montesinos, Pau
Baer, Maria R.
Larson, Richard A.
Ustun, Celalettin
Fabbiano, Francesco
Di Stasi, Antonio
Stuart, Robert
Olin, Rebecca
Kasner, Margaret
Ciceri, Fabio
Chou, Wen-Chien
Podoltsev, Nikolai
Recher, Christian
Yokoyama, Hisayuki
Hosono, Naoko
Yoon, Sung-Soo
Lee, Je-Hwan
Pardee, Timothy
Fathi, Amir T.
Liu, Chaofeng
Liu, Xuan
Bahceci, Erkut
Levis, Mark J.
CANCER RESEARCH, 2019, 79 (13)
[22] Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia
Wang, Jianxiang
Jiang, Bin
Li, Jian
Liu, Ligen
Du, Xin
Jiang, Hao
Hu, Jianda
Yuan, Menghe
Sakatani, Taishi
Kadokura, Takeshi
Takeuchi, Masato
Kosako, Masanori
Ma, Xiao
Girshova, Larisa
Tan, Jerome
Bondarenko, Sergey
Lee, Lily Wong Lee
Khuhapinant, Archrob
Martynova, Elena
Hasabou, Nahla
LEUKEMIA, 2024, 38 (11) : 2410 - 2418
[23] Gilteritinib and Venetoclax for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia - a Real-World Multicenter Retrospective Study
Kugler, Eitan
Cohen, Inbar
Ram, Ron
Canaani, Jonathan
Amitai, Irina
Shargian, Liat
Nachmias, Boaz
Krayem, Baher
Frisch, Avraham
Levi, Itay
Akria, Luiza
Raanani, Pia
Wolach, Ofir
Kugler, Eitan
BLOOD, 2023, 142
[24] Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Updated Analyses of a Phase 1b Study
Altman, Jessica K.
Daver, Naval
Maly, Joseph
Levis, Mark
Ritchie, Ellen
Litzow, Mark
McCloskey, James
Smith, Catherine C.
Schiller, Gary
Bradley, Terrence
Tiu, Ramon V.
Naqvi, Kiran
Siddani, Satya
Wang, Jing
Lee, Paul
Perl, Alexander E.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S285 - S285
[25] Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study
Daver, Naval
Altman, Jessica K.
Maly, Joseph
Levis, Mark
Ritchie, Ellen
Litzow, Mark
McCloskey, James K.
Smith, Catherine C.
Schiller, Gary J.
Bradley, Terrence
Tiu, Ramon V.
Hong, Wan-Jen
Tong, Bo
Qin, Qin
Dilley, Kimberley
Perl, Alexander E.
BLOOD, 2020, 136
[26] Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
Alexander E. Perl
Naoko Hosono
Pau Montesinos
Nikolai Podoltsev
Giovanni Martinelli
Nicki Panoskaltsis
Christian Recher
Catherine C. Smith
Mark J. Levis
Stephen Strickland
Christoph Röllig
Marco Groß-Langenhoff
Wen-Chien Chou
Je-Hwan Lee
Hisayuki Yokoyama
Nahla Hasabou
Qiaoyang Lu
Ramon V. Tiu
Jessica K. Altman
Blood Cancer Journal, 12
[27] Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
Perl, Alexander E.
Hosono, Naoko
Montesinos, Pau
Podoltsev, Nikolai
Martinelli, Giovanni
Panoskaltsis, Nicki
Recher, Christian
Smith, Catherine C.
Levis, Mark J.
Strickland, Stephen
Rollig, Christoph
Gross-Langenhoff, Marco
Chou, Wen-Chien
Lee, Je-Hwan
Yokoyama, Hisayuki
Hasabou, Nahla
Lu, Qiaoyang
Tiu, Ramon, V
Altman, Jessica K.
BLOOD CANCER JOURNAL, 2022, 12 (05)
[28] Italian Real-World Experience of Gilteritinib Monotherapy in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Preliminary Results
Greco, Rosa
Imbergamo, Silvia
Pierdomenico, Elisabetta
Di Camillo, Barbara
Papayannidis, Cristina
Todisco, Elisabetta
Borlenghi, Erika
Fracchiolla, Nicola
Basilico, Claudia
Fumagalli, Monica
Zappasodi, Patrizia
Turrini, Mauro
Candoni, Anna
Lunghi, Monia
Musso, Maurizio
Vetro, Calogero
Guolo, Fabio
Mannina, Donato
Lico, Albana
Scattolin, Anna Maria
Nadali, Gianpaolo
Crugnola, Monica
Galimberti, Sara
Marchesi, Francesco
Metafuni, Elisabetta
di Toritto, Tommaso Caravita
Minotti, Clara
Musto, Pellegrino
Mancini, Valentina
Riva, Marta
Rizzo, Lorenzo
Grillo, Giovanni
Cairoli, Roberto
BLOOD, 2024, 144 : 5188 - 5189
[29] Gilteritinib-based combination therapy in adult relapsed/refractory FLT3-mutated acute myeloid leukaemia
Chen, Nianci
Pan, Jiajia
Zhou, Yile
Mao, Liping
Lou, Yinjun
Qian, Jiejing
Xu, Gaixiang
Wei, Juying
Zhou, De
Shou, Lihong
Huang, Li
Yan, Minchao
Zeng, Hui
Fan, Cuihua
Wu, Gongqiang
Feng, Weiying
Tong, Hongyan
Jin, Jie
Wang, Huafeng
BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (03) : 861 - 870
[30] Follow-up of patients with FLT3-mutated R/R AML in the phase 3 ADMIRAL trial.
Perl, Alexander E.
Larson, Richard A.
Podoltsev, Nikolai Alexandrovich
Strickland, Stephen
Wang, Eunice S.
Schiller, Gary J.
Martinelli, Giovanni
Neubauer, Andreas
Sierra, Jorge
Montesinos, Pau
Recher, Christian
Yoon, Sung-Soo
Hosono, Naoko
Onozawa, Masahiro
Chiba, Shigeru
Kim, Hee-Je
Hasabou, Nahla
Lu, Qiaoyang
Tiu, Ramon Velasquez
Levis, Mark J.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →